N.I.H. Workers Denounce Trump's ‘Harmful' Health Policies
More than 60 employees of the National Institutes of Health signed their names to a scathing letter sent on Monday to denounce what they described as the degradation of the country's medical research apparatus under President Trump, accusing the administration of illegally withholding money, endangering participants in studies and censoring critical research.
The letter, sent to Dr. Jay Bhattacharya, the N.I.H. director, and then posted online, was a remarkable rebuke of the agency's leadership. In interviews, signatories to the letter said that they were concerned they could be fired for speaking out, but that the risks of acquiescing to orders they saw as unethical — and in some cases illegal — were too great.
'We dissent to administration policies that undermine the N.I.H. mission, waste public resources, and harm the health of Americans and people across the globe,' they wrote in the four-page letter. 'Many have raised these concerns to N.I.H. leadership, yet we remain pressured to implement harmful measures.'
The letter included signatories from across the agency's 27 institutes and centers. Its organizers called it 'The Bethesda Declaration,' a reference both to the home of the agency's headquarters and to a 2020 missive by Dr. Bhattacharya, the Great Barrington Declaration, opposing Covid lockdowns in 2020. In that letter, he and his co-authors argued for dispensing with the lockdowns in the interest of letting the virus spread among younger, healthier people.
Dr. Bhattacharya, who was then a health economist and professor of medicine at Stanford University, has described feeling bruised by heavy criticism of the idea, including from N.I.H officials. After he was nominated to lead the agency, he promised to 'establish a culture of respect for free speech in science and scientific dissent at the N.I.H.'
With the letter, some of his employees are putting that promise to the test. 'We hope you will welcome this dissent,' they wrote.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
39 minutes ago
- Medscape
ASCO 2025: Key Updates in Early Breast Cancer Care
Mariana Chavez MacGregor, MD, MSc, comments on how the ASCO 2025 meeting delivered a wealth of impactful data, particularly in the early-stage breast cancer setting. Trials like neoCARHP and CompassHER2 raised important questions about de-escalating therapy for HER2-positive patients, challenging the role of carboplatin and demonstrating strong pathologic complete response rates with shorter regimens. Long-term data from SOFT and TEXT reinforced the survival benefits of ovarian suppression plus an aromatase inhibitor in high-risk premenopausal patients, and the OASIS 4 study showed promise with elinzanetant in managing vasomotor symptoms. Across subtypes, including triple-negative disease, and with the growing role of AI and circulating tumor DNA, the meeting emphasized more personalized, less toxic approaches to care.
Medscape
39 minutes ago
- Medscape
ASCO 2025: Key Highlights in Advanced Lung Cancer
Just returned from ASCO 2025, Isabel Preeshagul, DO, comments on intriguing data that were presented, including results from REZILIENT1, which showed a 35% response rate for zipalertinib in patients with epidermal growth factor receptor exon 20-altered stage IV non-small cell lung cancer (NSCLC), even those previously treated with targeted therapies, with manageable toxicity. An unexpected finding from another study in the advanced NSCLC space suggested that administering immunochemotherapy before 3:00 PM was associated with better outcomes, possibly due to circadian influences on immune response. In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.
Medscape
an hour ago
- Medscape
NHS Blood Supplies Running Low Amid Donor Shortage
NHS Blood and Transplant (NHSBT) has issued an urgent call for more blood donors 'to stabilise the nation's blood supply', warning that stocks of O negative red cells are nearing red alert status. NHSBT said there was an annual shortfall of 200,000 donors needed to meet growing demand. Dr Jo Farrar, the body's chief executive, said that maintaining stocks over the past 12 months had been 'challenging'. Cyber-Attack Led to Acute Shortage The supply problem was exacerbated by last summer's ransomware attack on several London hospitals. The disruption to cross-matching procedures forced clinicians to rely on O negative blood. This blood type is known as the 'universal donor' because it can be given to patients of any blood group without triggering a transfusion reaction. Just 8% of the population has O negative blood but it accounts for 16% of hospital demand. As the ransomware threat unfolded, NHSBT shut down multiple IT systems as a precautionary measure. This led to major disruptions in blood collection and transport. Several London hospitals declared critical incidents, cancelled surgeries and tests, and faced transfusion delays. Blood Stocks Remain Critically Low NHSBT said stocks have yet to recover, with current levels strained by a recent series of bank holidays falling in quick succession. NHSBT aims to maintain 6 days' stock of red blood cells. As of 9 am on 9 June, supplies of O-, B-, AB-, O+, and A+ all fell below that threshold, with O- at just 3.4 days. Only A-, B+, and AB+ blood types registered more than 6 days of stock. A letter sent to senior managers and practitioners on 21 May warned that the ongoing amber alert for group O red cells could escalate to a red alert. A pre-amber alert remains in place for group B D-negative red cells. The letter urged adherence to the National Blood Transfusion Committee's red cell shortage plan which was updated in October 2024. Call for One Million Active Donors To meet NHS demand safely, NHSBT said it needs one million regular blood donors. However, its most recent analysis showed participation fell short by over 200,000. Despite an increase in new donor registrations over the past year, only 24% of registrants went on to give blood. Currently, just 2% of the population is supporting the country's blood supply. In support of National Blood Week (9-15 June), NHSBT urged people to join 'the country's largest volunteering force' by donating blood. Focus on Donors with Ro Subtype NHSBT highlighted a critical need for more donors of Black Caribbean and Black African heritage. Around half of people in these groups have the Ro subtype, vital for treating sickle cell disease, the UK's fastest growing genetic blood disorder. In a press release, Health Minister Baroness Merron said: 'The NHS is in urgent need of more lifesaving blood donors from all backgrounds. We are working alongside NHSBT to make donating blood easier than ever before, opening up new donor centres and making appointments available closer to home.'
